SLC26A10

Across TCGA pan-cancer cohorts, SLC26A10 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC26A10 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SLC26A10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC26A10 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, ESCA, and SARC are the cancer types where SLC26A10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
SARC	DFS	Median	All	0.081	0.632	<.001	6	view →
UCEC	DFS	Median	All	0.959	0.625	.020	6	view →
CESC	OS	Median	All	0.601	0.876	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC26A10–ACC (DFS)

Open the ACC breakdown →